首页> 美国卫生研究院文献>Chinese Medical Journal >Clinical efficacy of the modified Helicobacter pylori eradication therapy for Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma: a meta analysis
【2h】

Clinical efficacy of the modified Helicobacter pylori eradication therapy for Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma: a meta analysis

机译:改良的幽门螺杆菌根除疗法对幽门螺杆菌阴性胃黏膜相关淋巴样淋巴瘤的临床疗效:荟萃分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

(HP) has been considered to be one of the primary causes of gastric mucosa-associated lymphoid tissue (MALT) lymphoma since 1993. Low-grade gastric MALT lymphoma with HP is widely treated with HP eradication therapy, according to each specific clinical situation. However, several studies and guidelines indicate that the modified HP eradication therapy is also valid for HP-negative gastric MALT lymphoma. The aim of this study was to perform a meta-analysis of the clinical efficacy of the modified HP eradication therapy for gastric MALT lymphoma without HP.
机译:自1993年以来,HP(HP)被认为是引起胃黏膜相关淋巴组织(MALT)淋巴瘤的主要原因之一。根据每种具体的临床情况,根除HP的低度胃MALT淋巴瘤已被HP根除疗法广泛治疗。但是,一些研究和指南表明,改良的HP根除疗法对HP阴性的胃MALT淋巴瘤也有效。这项研究的目的是对改良型HP根除疗法治疗无HP的胃MALT淋巴瘤的临床疗效进行荟萃分析。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号